314 related articles for article (PubMed ID: 33249060)
21. Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.
Li Y; Yi L; Cheng S; Wang Y; Wang J; Sun J; Zhang Q; Xu X
J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33416466
[TBL] [Abstract][Full Text] [Related]
22. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267
[TBL] [Abstract][Full Text] [Related]
23. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.
Vitner EB; Achdout H; Avraham R; Politi B; Cherry L; Tamir H; Yahalom-Ronen Y; Paran N; Melamed S; Erez N; Israely T
J Biol Chem; 2021; 296():100470. PubMed ID: 33639165
[TBL] [Abstract][Full Text] [Related]
24. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2
Good SS; Westover J; Jung KH; Zhou XJ; Moussa A; La Colla P; Collu G; Canard B; Sommadossi JP
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558299
[TBL] [Abstract][Full Text] [Related]
25. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
26. The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
Müller C; Obermann W; Karl N; Wendel HG; Taroncher-Oldenburg G; Pleschka S; Hartmann RK; Grünweller A; Ziebuhr J
Antiviral Res; 2021 Feb; 186():105012. PubMed ID: 33422611
[TBL] [Abstract][Full Text] [Related]
27. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus.
Terrier O; Dilly S; Pizzorno A; Chalupska D; Humpolickova J; Bouřa E; Berenbaum F; Quideau S; Lina B; Fève B; Adnet F; Sabbah M; Rosa-Calatrava M; Maréchal V; Henri J; Slama-Schwok A
Molecules; 2021 Apr; 26(9):. PubMed ID: 33946802
[TBL] [Abstract][Full Text] [Related]
28. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
29. Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity.
Rand U; Kupke SY; Shkarlet H; Hein MD; Hirsch T; Marichal-Gallardo P; Cicin-Sain L; Reichl U; Bruder D
Cells; 2021 Jul; 10(7):. PubMed ID: 34359926
[TBL] [Abstract][Full Text] [Related]
30. Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice.
Muturi E; Hong W; Li J; Yang W; He J; Wei H; Yang H
Int J Antimicrob Agents; 2022 Jan; 59(1):106499. PubMed ID: 34929295
[TBL] [Abstract][Full Text] [Related]
31. Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid Interface Cultured Human Primary Bronchial Epithelial Cells.
Ter Ellen BM; Dinesh Kumar N; Bouma EM; Troost B; van de Pol DPI; van der Ende-Metselaar HH; Apperloo L; van Gosliga D; van den Berge M; Nawijn MC; van der Voort PHJ; Moser J; Rodenhuis-Zybert IA; Smit JM
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372541
[TBL] [Abstract][Full Text] [Related]
32. Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.
Coelho AR; Oliveira PJ
Eur J Clin Invest; 2020 Oct; 50(10):e13366. PubMed ID: 32735689
[No Abstract] [Full Text] [Related]
33. Gallium maltolate has
Bernstein LR; Zhang L
Antivir Chem Chemother; 2020; 28():2040206620983780. PubMed ID: 33353394
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.
Plaze M; Attali D; Prot M; Petit AC; Blatzer M; Vinckier F; Levillayer L; Chiaravalli J; Perin-Dureau F; Cachia A; Friedlander G; Chrétien F; Simon-Loriere E; Gaillard R
Int J Antimicrob Agents; 2021 Mar; 57(3):106274. PubMed ID: 33387629
[TBL] [Abstract][Full Text] [Related]
35. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis.
Hoffmann HH; Kunz A; Simon VA; Palese P; Shaw ML
Proc Natl Acad Sci U S A; 2011 Apr; 108(14):5777-82. PubMed ID: 21436031
[TBL] [Abstract][Full Text] [Related]
36. Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
Kashyap T; Murray J; Walker CJ; Chang H; Tamir S; Hou B; Shacham S; Kauffman MG; Tripp RA; Landesman Y
Antiviral Res; 2021 Aug; 192():105115. PubMed ID: 34157321
[TBL] [Abstract][Full Text] [Related]
37. Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro.
Akaberi D; Krambrich J; Ling J; Luni C; Hedenstierna G; Järhult JD; Lennerstrand J; Lundkvist Å
Redox Biol; 2020 Oct; 37():101734. PubMed ID: 33007504
[TBL] [Abstract][Full Text] [Related]
38. Quinacrine as a potential treatment for COVID-19 virus infection.
Pineda B; Pérez de la Cruz V; Hernández Pando R; Sotelo J
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):556-566. PubMed ID: 33506949
[TBL] [Abstract][Full Text] [Related]
39. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway.
Ma Q; Li R; Pan W; Huang W; Liu B; Xie Y; Wang Z; Li C; Jiang H; Huang J; Shi Y; Dai J; Zheng K; Li X; Hui M; Fu L; Yang Z
Phytomedicine; 2020 Nov; 78():153296. PubMed ID: 32890913
[TBL] [Abstract][Full Text] [Related]
40. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]